<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00650819</url>
  </required_header>
  <id_info>
    <org_study_id>P03757</org_study_id>
    <nct_id>NCT00650819</nct_id>
  </id_info>
  <brief_title>Comparison of Ezetimibe Plus Simvastatin Versus Ezetimibe or Simvastatin Alone in Subjects With Primary Hypercholesterolemia (Study P03757)(COMPLETED)</brief_title>
  <official_title>A Multicenter, Double-blind, Randomized, Active-controlled Parallel Groups Study Comparing The Efficacy and Safety of The Daily Co-Administration of Ezetimibe 10 mg With Simvastatin 20 mg Vs Simvastatin Or Ezetimibe Alone in Subjects With Primary Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double blind; active-controlled parallel groups study
      enrolling subjects with primary hypercholesterolemia. Subjects receive ezetimibe,
      simvastatin, or the combination once daily for 8 weeks to determine the effect on
      LDL-cholesterol.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2004</start_date>
  <completion_date type="Actual">February 1, 2005</completion_date>
  <primary_completion_date type="Actual">February 1, 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change from baseline in LDL-C concentration.</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in total cholesterol, triglycerides, and HDL-C.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Ezetimibe + Simvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Simvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ezetimibe</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe + Simvastatin</intervention_name>
    <description>ezetimibe 10 mg plus simvastatin 20 mg once daily for 8 weeks</description>
    <arm_group_label>Ezetimibe + Simvastatin</arm_group_label>
    <other_name>SCH 58235</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>simvastatin 20 mg plus ezetimibe placebo once daily for 8 weeks</description>
    <arm_group_label>Simvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe</intervention_name>
    <description>Ezetimibe 10 mg plus simvastatin placebo once daily for 8 weeks</description>
    <arm_group_label>Ezetimibe</arm_group_label>
    <other_name>SCH 58235</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must demonstrate their willingness to participate in the study and comply
             with its procedures by signing a written informed consent.

          -  Subjects must be &gt;= 18 years and &lt;= 75 years of age.

          -  Subjects with Primary Hypercholesterolemia must be finished the Lab test listed below
             and the results must be available at the time of randomization at Visit 3 (Baseline
             Visit).

               -  LDL-C concentration &gt; 3.64 mmol/L (140mg/dL) to &lt;= 6.3 mmol/L (250 mg/dL) using
                  the Friedewald calculation

               -  Total cholesterol (TC) &gt; 5.2mmol/L (200mg/dL) to &lt; 12.7mmol/L (500mg/dL)

               -  Triglyceride concentrations of &lt;= 3.99 mmol/L (350 mg/dL)

               -  Liver transaminases (ALT, AST) must be within normal limits, with no active liver
                  disease and CK &lt; 50% above the upper limit of normal

               -  Clinical laboratory tests (CBC, blood chemistries, urinalysis) must be within
                  normal limits

          -  Subjects must report a stable weight history for at least 4 weeks prior to entry into
             study at Visit 3 (Baseline Visit).

          -  Women of childbearing potential (includes women who are less than 1 year
             postmenopausal and women who become sexually active) must be using an acceptable
             method of birth control (e.g. medically prescribed IUD, condom in combination with
             spermicide) or be surgically sterilized (e.g., hysterectomy or tubal ligation).

          -  Subjects must be free of any clinically significant diseases other than hyperlipidemia
             that would interfere with study evaluations.

          -  Subjects must understand and be able to adhere to the dosing and visit schedules, and
             must agree to remain on a cholesterol-lowering diet for the duration of the study.

        Exclusion Criteria:

          -  Subjects whose body mass index (BMI = weight [kg]/height2 [m]) is &gt;= 30 Kg/m^2 at
             Visit 3 (Baseline Visit).

          -  Subjects who have known hypersensitivity to HMG-CoA reductase inhibitors.

          -  Subjects who consume &gt; 14 alcoholic drinks per week. (A drink is: a can of beer, glass
             of wine, or single measure of spirits).

          -  Any condition or situation, which in the opinion of the investigator, might pose a
             risk to the subject or interfere with participation in the study.

          -  Women who are pregnant or nursing

          -  Subjects who have not observed the designated washout periods for any of the
             prohibited medications outlined in protocol

          -  Congestive heart failure defined by NYHA as Class III or IV.

          -  Uncontrolled cardiac arrhythmia.

          -  Myocardial infarction, coronary bypass surgery or angioplasty within 6 months of study
             entry.

          -  Unstable or severe peripheral artery disease within 3 months of study entry.

          -  Unstable angina pectoris within 6 months of study entry.

          -  Uncontrolled hypertension (treated or untreated) with systolic blood pressure &gt; 160 mm
             Hg or diastolic &gt; 100 mm Hg of study entry.

          -  Uncontrolled (as determined by HbA1c &gt; 7 %) or newly diagnosed (within 1month of study
             entry) diabetes mellitus.

          -  Uncontrolled endocrine or metabolic disease known to influence serum lipids or
             lipoproteins, i.e., secondary causes of hyperlipidemia, such as secondary
             hypercholesterolemia due to hypothyroidism (TSH above upper limit of normal). Subjects
             with a history of hypothyroidism who are on a stable therapy of thyroid hormone
             replacement for at least 6 weeks are eligible for enrollment if TSH levels are within
             normal limits before enrollment.

          -  Known Impaired renal function (plasma creatinine &gt; 2.0 mg/dL), or nephrotic syndrome
             of study entry.

          -  Disorders of the hematologic, digestive, or central nervous systems including
             cerebrovascular disease and degenerative disease that would limit study evaluation or
             participation.

          -  Known HIV positive.

          -  Cancer within the past 5 years (except for successfully treated basal and squamous
             cell carcinomas).

          -  History of mental instability, drug/alcohol abuse within the past 5 years, or major
             psychiatric illness not adequately controlled and stable on pharmacotherapy.

          -  Subjects with known coagulopathy (PT and PTT at Visit 1 &gt;1.25 times control)

          -  Women receiving hormonal therapy, including hormone replacement, any estrogen
             antagonist/agonist, or oral contraceptives.

          -  Any other condition which in the opinion of the investigator would make the patient
             unsuitable for enrollment, or could interfere with the patient participating in and
             completing the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2008</study_first_submitted>
  <study_first_submitted_qc>March 31, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2008</study_first_posted>
  <last_update_submitted>May 10, 2017</last_update_submitted>
  <last_update_submitted_qc>May 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
    <mesh_term>Ezetimibe, Simvastatin Drug Combination</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/policies-perspectives.html</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

